Journal
JOURNAL OF TRANSLATIONAL MEDICINE
Volume 19, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12967-021-03058-z
Keywords
Angiogenesis; Bufalin; Colorectal cancer; STAT3; Tumour microenvironment
Categories
Funding
- Science and technology innovation project of Putuo District Health system [ptkwws201905]
- Budget project of Shanghai University of Traditional Chinese Medicine [2019LK039]
- Natural Science Foundation of Shanghai [20ZR1450500, 19ZR1413800]
- National Nature Science Foundation of China [81873137]
Ask authors/readers for more resources
This study found that bufalin inhibits tumor microenvironment-mediated angiogenesis by targeting the STAT3 signaling pathway in vascular endothelial cells. This suggests that bufalin may be used as a new antiangiogenic adjuvant therapy for treating colorectal cancer.
Background Antiangiogenic therapy has increasingly become an important strategy for the treatment of colorectal cancer. Recent studies have shown that the tumour microenvironment (TME) promotes tumour angiogenesis. Bufalin is an active antitumour compound whose efficacy has been indicated by previous studies. However, there are very few studies on the antiangiogenic effects of bufalin. Methods Herein, human umbilical vein endothelial cell (HUVEC) tube formation, migration and adhesion tests were used to assess angiogenesis in vitro. Western blotting and quantitative PCR were used to detect relevant protein levels and mRNA expression levels. A subcutaneous xenograft tumour model and a hepatic metastasis model were established in mice to investigate the influence of bufalin on angiogenesis mediated by the TME in vivo. Results We found that angiogenesis mediated by cells in the TME was significantly inhibited in the presence of bufalin. The results demonstrated that the proangiogenic genes in HUVECs, such as VEGF, PDGFA, E-selectin and P-selectin, were downregulated by bufalin and that this downregulation was mediated by inhibition of the STAT3 pathway. Overexpression of STAT3 reversed the inhibitory effects of bufalin on angiogenesis. Furthermore, there was little reduction in angiogenesis when bufalin directly acted on the cells in the tumour microenvironment. Conclusion Our findings demonstrate that bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway in vascular endothelial cells, revealing that bufalin may be used as a new antiangiogenic adjuvant therapy medicine to treat colorectal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available